BBK Worldwide, a clinical trial marketing firm announced it is making the availability of its mobile apps My Clinical Study Buddy®for patients and My Protocol Pal® for investigators free of charge throughout 2015.
BBK Makes Mobile App Suite Available Free of Charge
BBK Worldwide, a clinical trial marketing firm announced it is making the availability of its mobile apps My Clinical Study Buddy® for patients and My Protocol PalSM for investigators free of charge throughout 2015. BBK’s mobile apps are built on its cloud-based content management engine, TrialCentralNetSM (TCN®), to help companies reduce enrollment timelines and provide insight into key patient recruitment pressure points. What’s more, BBK’s engagement solutions, RSG® Card and RSG® Arrive are also available through TCN for a seamless connection to My Clinical Study Buddy®. These offerings allow the study community to more easily reimburse and arrange travel for relevant studies, a major and often overlooked bottleneck for sites and sponsors – especially with the complex travel and reimbursements inherent in rare disease trials.
Read the full release here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
September 10th 2024The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.